Ghent University Academic Bibliography

Journal Article
A1
open access

Worldwide trends in underweight and obesity from 1990 to 2022 : a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults

Nowell H Phelps, Rosie K Singleton, Bin Zhou, Rachel A Heap, Anu Mishra, James E Bennett, Christopher J Paciorek, Victor PF Lhoste, Rodrigo M Carrillo-Larco, Gretchen A Stevens, et al.

(2024) LANCET. 403(10431). p.1027-1050

Add to list

Miscellaneous

Global access and patient safety in the transition to environmentally friendly respiratory inhalers : the Global Initiative for Asthma perspective

Mark L Levy, Eric D Bateman, Keith Allan, Leonard B Bacharier, Matteo Bonini, Louis-Philippe Boulet, Arnaud Bourdin, Chris Brightling, Guy Brusselle (UGent) , Roland Buhl, et al.

(2023) LANCET. 402(10406). p.1012-1016

Add to list

Journal Article
A1
open access

Systemic sclerosis

Elizabeth R Volkmann, Kristofer Andréasson and Vanessa Smith (UGent)

(2023) LANCET. 401(10373). p.304-318

Add to list

Miscellaneous

What water will the UN Conference carry forward : a fundamental human right or a commodity?

Léo Heller, Meera Karunananthan, Margreet Zwarteveen, David Hall, Mary Ann Manahan (UGent) and Fatou Diouf

(2023) LANCET. 402(10404). p.757-759

Add to list

Small babies, big risks : global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting

Joy E Lawn, Eric O Ohuma, Ellen Bradley, Lorena Suárez Idueta, Elizabeth Hazel, Yemisrach B Okwaraji, Daniel J Erchick, Judith Yargawa, Joanne Katz, Anne C C Lee, et al.

(2023) LANCET. 401(10389). p.1707-1719

Add to list

Conference Paper

Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review

Yasmine Khan (UGent) , Nick Verhaeghe (UGent) , Brecht Devleesschauwer (UGent) , Lisa Cavillot, Sylvie Gadeyne, Nele Pauwels (UGent) , Laura Van den Borre and Delphine De Smedt (UGent)

(2023) LANCET. 402. p.61-61

Add to list

Miscellaneous

Classification of COPD : fostering prevention and precision medicine in the Lancet Commission on COPD

Guy Brusselle (UGent) and Marc Humbert

(2022) LANCET. 400(10356). p.869-871

Add to list

Health-care workers and facilities in Ukraine must be protected

Sally McCarthy, Katherine Henderson, Clare Skinner, Luis Daniel Sánchez Arreola, Chip-Jin Ng, Aus N Jamil, Patrick Van de Voorde (UGent) , Arif Alper Cevik, Michael von Schickfus, Richard Santos, et al.

(2022) LANCET. 399(10332). p.1299-1299

Add to list

Miscellaneous

New global WHO postnatal guidance is welcome but misses the long-term perspective

Debra Bick, Uma Ram, Ponnusamy Saravanan and Marleen Temmerman (UGent)

(2022) LANCET. 399(10335). p.1578-1580

Add to list

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

Atul Deodhar, Filip Van den Bosch (UGent) , Denis Poddubnyy, Walter P Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, et al.

(2022) LANCET. 400(10349). p.369-379

Academic Bibliography

Worldwide trends in underweight and obesity from 1990 to 2022 : a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults

Global access and patient safety in the transition to environmentally friendly respiratory inhalers : the Global Initiative for Asthma perspective

Systemic sclerosis

What water will the UN Conference carry forward : a fundamental human right or a commodity?

Small babies, big risks : global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting

Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review

Classification of COPD : fostering prevention and precision medicine in the Lancet Commission on COPD

Health-care workers and facilities in Ukraine must be protected

New global WHO postnatal guidance is welcome but misses the long-term perspective

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2) : a randomised, double-blind, placebo-controlled, phase 3 trial

Contents

Support

Contact